First Week Of December 21st Options Trading For BioMarin Pharmaceutical (BMRN)

Investors in BioMarin Pharmaceutical Inc. ( BMRN) saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMRN options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

The put contract at the $65.00 strike price has a current bid of $4.70. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $65.00, but will also collect the premium, putting the cost basis of the shares at $60.30 (before broker commissions). To an investor already interested in purchasing shares of BMRN, that could represent an attractive alternative to paying $67.13/share today.

Because the $65.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 60%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 7.23% return on the cash commitment, or 44.70% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for BioMarin Pharmaceutical Inc., and highlighting in green where the $65.00 strike is located relative to that history:

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half